Humana Inc. (NYSE:HUM)‘s stock had its “neutral” rating restated by analysts at UBS AG in a research report issued on Wednesday, www.flashratings.com reports. They currently have a $250.00 target price on the insurance provider’s stock, up from their prior target price of $237.00. UBS AG’s price target points to a potential downside of 1.95% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $256.00 price objective for the company in a research note on Monday, May 8th. Argus upgraded Humana from a “hold” rating to a “buy” rating and set a $260.00 price objective for the company in a research note on Friday, June 9th. BidaskClub upgraded Humana from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Citigroup Inc. started coverage on Humana in a research note on Wednesday, June 28th. They issued a “buy” rating and a $275.00 price objective for the company. Finally, Bank of America Corporation boosted their price objective on Humana from $270.00 to $275.00 and gave the company a “buy” rating in a research note on Friday, July 14th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company. Humana has a consensus rating of “Hold” and an average price target of $243.65.

Humana (NYSE HUM) traded up 1.89% during trading on Wednesday, reaching $254.96. 1,353,904 shares of the company’s stock were exchanged. The stock has a market capitalization of $36.85 billion, a PE ratio of 20.97 and a beta of 0.91. Humana has a 52 week low of $163.50 and a 52 week high of $255.10. The stock has a 50-day moving average of $237.33 and a 200-day moving average of $221.21.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.08 by $0.41. Humana had a return on equity of 15.85% and a net margin of 3.37%. The company had revenue of $13.53 billion during the quarter, compared to analysts’ expectations of $13.61 billion. During the same quarter in the previous year, the business earned $2.30 earnings per share. On average, equities research analysts anticipate that Humana will post $11.45 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Humana’s (HUM) Neutral Rating Reiterated at UBS AG” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.watchlistnews.com/humanas-hum-neutral-rating-reiterated-at-ubs-ag/1466493.html.

In other Humana news, SVP Brian P. Leclaire sold 4,971 shares of the stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total value of $1,193,040.00. Following the completion of the transaction, the senior vice president now owns 14,258 shares in the company, valued at $3,421,920. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Heidi S. Margulis sold 1,500 shares of the stock in a transaction on Friday, May 26th. The stock was sold at an average price of $231.96, for a total value of $347,940.00. Following the completion of the transaction, the vice president now owns 8,150 shares of the company’s stock, valued at approximately $1,890,474. The disclosure for this sale can be found here. Corporate insiders own 0.80% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Independent Portfolio Consultants Inc. raised its stake in Humana by 22.1% in the second quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock valued at $125,000 after buying an additional 94 shares during the period. Fiduciary Trust Co. purchased a new stake in Humana during the second quarter valued at $135,000. Guardian Life Insurance Co. of America raised its stake in Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock valued at $119,000 after buying an additional 4 shares during the period. Point72 Asia Hong Kong Ltd purchased a new stake in Humana during the first quarter valued at $128,000. Finally, Westbourne Investment Advisors Inc. purchased a new stake in Humana during the second quarter valued at $205,000. 99.66% of the stock is currently owned by institutional investors.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.